I
321.36
0.36 (0.11%)
| Previous Close | 321.00 |
| Open | 319.00 |
| Volume | 615,511 |
| Avg. Volume (3M) | 911,733 |
| Market Cap | 22,615,674,880 |
| Price / Earnings (TTM) | 57.80 |
| Price / Earnings (Forward) | 75.76 |
| Price / Sales | 10.42 |
| Price / Book | 16.39 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | 18.29% |
| Operating Margin (TTM) | 15.61% |
| Diluted EPS (TTM) | 5.55 |
| Quarterly Revenue Growth (YOY) | 28.80% |
| Quarterly Earnings Growth (YOY) | -31.30% |
| Total Debt/Equity (MRQ) | 131.40% |
| Current Ratio (MRQ) | 4.47 |
| Operating Cash Flow (TTM) | 406.50 M |
| Levered Free Cash Flow (TTM) | 84.25 M |
| Return on Assets (TTM) | 6.94% |
| Return on Equity (TTM) | 37.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Insulet Corporation | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.38 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.29% |
| % Held by Institutions | 102.73% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 380.00 (Citigroup, 18.25%) | Buy |
| 380.00 (Goldman Sachs, 18.25%) | Buy | |
| Median | 360.00 (12.02%) | |
| Low | 266.00 (Barclays, -17.23%) | Hold |
| Average | 346.43 (7.80%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 308.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 16 Jun 2025 | 365.00 (13.58%) | Buy | 306.59 |
| Goldman Sachs | 30 May 2025 | 380.00 (18.25%) | Buy | 325.03 |
| Raymond James | 27 May 2025 | 360.00 (12.02%) | Buy | 326.64 |
| Citigroup | 22 May 2025 | 380.00 (18.25%) | Buy | 321.00 |
| Wolfe Research | 13 May 2025 | 350.00 (8.91%) | Buy | 314.46 |
| Oppenheimer | 09 May 2025 | 324.00 (0.82%) | Buy | 310.67 |
| Barclays | 30 Apr 2025 | 266.00 (-17.23%) | Hold | 252.29 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Jun 2025 | Announcement | Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions |
| 10 Jun 2025 | Announcement | Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users |
| 23 May 2025 | Announcement | Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 |
| 13 May 2025 | Announcement | Insulet Announces Publication of 2024 Sustainability Report |
| 08 May 2025 | Announcement | Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency¹) |
| 28 Apr 2025 | Announcement | Insulet Appoints Ashley McEvoy President and CEO |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |